Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Abrahamsen, B
Adachi, JD
Brandi, ML
Bruyère, Olivier ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Compston, J
Ducy, P
Ferrari, S
Harvey, NC
Kanis, JA
Karsenty, G
Laslop, A
Rabenda, Véronique ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Bliziotes M. Update in serotonin and bone. J Clin Endocrinol Metab 2010, 95:4124-4132.
Brand T., Anderson G.M. The measurement of platelet-poor plasma serotonin: a systematic review of prior reports and recommendations for improved analysis. Clin Chem 2011, 57:1376-1386.
Bliziotes M., Gunness M., Eshleman A., Wiren K. The role of dopamine and serotonin in regulating bone mass and strength: studies on dopamine and serotonin transporter null mice. J Musculoskelet Neuronal Interact 2002, 2:291-295.
Goltzman D. LRP5, Serotonin, and bone: complexity, contradictions, and conundrums. J Bone Miner Res 2011, 26:1997-2001.
Yadav V.K., Ryu J.H., Suda N., et al. Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell 2008, 135:825-837.
Yadav V.K., Balaji S., Suresh P.S., et al. Pharmacological inhibition of gut-derived serotonin synthesis is a potential bone anabolic treatment for osteoporosis. Nat Med 2010, 16:308-312.
Cui Y., Niziolek P.J., MacDonald B.T., et al. Lrp5 functions in bone to regulate bone mass. Nat Med 2011, 17:684-691.
Yadav V.K., Oury F., Suda N., et al. A serotonin-dependent mechanism explains the leptin regulation of bone mass, appetite, and energy expenditure. Cell 2009, 138:976-989.
Takeda S., Elefteriou F., Levasseur R., et al. Leptin regulates bone formation via the sympathetic nervous system. Cell 2002, 111:305-317.
Yirmiya R., Goshen I., Bajayo A., et al. Depression induces bone loss through stimulation of the sympathetic nervous system. Proc Natl Acad Sci U S A 2006, 103:16876-16881.
Warden S.J., Robling A.G., Sanders M.S., Bliziotes M.M., Turner C.H. Inhibition of the serotonin (5-hydroxytryptamine) transporter reduces bone accrual during growth. Endocrinology 2005, 146:685-693.
Warden S.J., Nelson I.R., Fuchs R.K., Bliziotes M.M., Turner C.H. Serotonin (5-hydroxytryptamine) transporter inhibition causes bone loss in adult mice independently of estrogen deficiency. Menopause 2008, 15:1176-1183.
Shim R.S., Baltrus P., Ye J., Rust G. Prevalence, treatment, and control of depressive symptoms in the United States: results from the National Health and Nutrition Examination Survey (NHANES), 2005-2008. J Am Board Fam Med 2011, 24:33-38.
Kessler R.C., Berglund P., Demler O., et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003, 289:3095-3105.
Alonso J., Angermeyer M.C., Bernert S., et al. Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand Suppl 2004, 420:21-27.
Moore M., Yuen H.M., Dunn N., Mullee M.A., Maskell J., Kendrick T. Explaining the rise in antidepressant prescribing: a descriptive study using the general practice research database. BMJ 2009, 339:b3999.
Bauer M., Monz B.U., Montejo A.L., et al. Prescribing patterns of antidepressants in Europe: results from the Factors Influencing Depression Endpoints Research (FINDER) study. Eur Psychiatry 2008, 23:66-73.
Whooley M.A., Kip K.E., Cauley J.A., Ensrud K.E., Nevitt M.C., Browner W.S. Depression, falls, and risk of fracture in older women. Study of Osteoporotic Fractures Research Group. Arch Intern Med 1999, 159:484-490.
Diem S.J., Blackwell T.L., Stone K.L., et al. Depressive symptoms and rates of bone loss at the hip in older women. J Am Geriatr Soc 2007, 55:824-831.
Wong S.Y., Lau E.M., Lynn H., et al. Depression and bone mineral density: is there a relationship in elderly Asian men? Results from Mr. Os (Hong Kong). Osteoporos Int 2005, 16:610-615.
Konstantynowicz J., Kadziela-Olech H., Kaczmarski M., et al. Depression in anorexia nervosa: a risk factor for osteoporosis. J Clin Endocrinol Metab 2005, 90:5382-5385.
Mussolino M.E., Jonas B.S., Looker A.C. Depression and bone mineral density in young adults: results from NHANES III. Psychosom Med 2004, 66:533-537.
Mezuk B., Eaton W.W., Golden S.H. Depression and osteoporosis: epidemiology and potential mediating pathways. Osteoporos Int 2008, 19:1-12.
Cizza G., Primma S., Coyle M., Gourgiotis L., Csako G. Depression and osteoporosis: a research synthesis with meta-analysis. Horm Metab Res 2010, 42:467-482.
Kanis J.A., Burlet N., Cooper C., et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2008, 19:399-428.
Atteritano M., Lasco A., Mazzaferro S., et al. Bone mineral density, quantitative ultrasound parameters and bone metabolism in postmenopausal women with depression. Intern Emerg Med 2011, [Electronic publication ahead of print].
Abrahamsen B., Brixen K. Mapping the prescriptiome to fractures in men-a national analysis of prescription history and fracture risk. Osteoporos Int 2009, 20:585-597.
Schwan S., Hallberg P. SSRIs, bone mineral density, and risk of fractures-a review. Eur Neuropsychopharmacol 2009, 19:683-692.
Tsapakis E.M., Gamie Z., Tran G.T., et al. The adverse skeletal effects of selective serotonin reuptake inhibitors. Eur Psychiatry 2012, 27:156-169.
Calarge C.A., Zimmerman B., Xie D., Kuperman S., Schlechte J.A. A cross-sectional evaluation of the effect of risperidone and selective serotonin reuptake inhibitors on bone mineral density in boys. J Clin Psychiatry 2010, 71:338-347.
Diem S.J., Blackwell T.L., Stone K.L., et al. Use of antidepressants and rates of hip bone loss in older women: the study of osteoporotic fractures. Arch Intern Med 2007, 167:1240-1245.
Haney E.M., Chan B.K., Diem S.J., et al. Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men. Arch Intern Med 2007, 167:1246-1251.
Kinjo M., Setoguchi S., Schneeweiss S., Solomon D.H. Bone mineral density in subjects using central nervous system-active medications. Am J Med 2005, 118:1414.
Richards J.B., Papaioannou A., Adachi J.D., et al. Effect of selective serotonin reuptake inhibitors on the risk of fracture. Arch Intern Med 2007, 167:188-194.
Spangler L., Scholes D., Brunner R.L., et al. Depressive symptoms, bone loss, and fractures in postmenopausal women. J Gen Intern Med 2008, 23:567-574.
Williams L.J., Henry M.J., Berk M., et al. Selective serotonin reuptake inhibitor use and bone mineral density in women with a history of depression. Int Clin Psychopharmacol 2008, 23:84-87.
Carvalho R.S., de Souza C.M., Neves J.C., et al. Effect of venlafaxine on bone loss associated with ligature-induced periodontitis in Wistar rats. J Negat Results Biomed 2010, 9:3.
Turker S., Karatosun V., Gunal I. Beta-blockers increase bone mineral density. Clin Orthop Relat Res 2006, 443:73-74.
Bonnet N., Pierroz D.D., Ferrari S.L. Adrenergic control of bone remodeling and its implications for the treatment of osteoporosis. J Musculoskelet Neuronal Interact 2008, 8:94-104.
Zamani A., Omrani G.R., Nasab M.M. Lithium's effect on bone mineral density. Bone 2009, 44:331-334.
French D.D., Campbell R., Spehar A., Cunningham F., Foulis P. Outpatient medications and hip fractures in the US: a national veterans study. Drugs Aging 2005, 22:877-885.
Schneeweiss S., Wang P.S. Association between SSRI use and hip fractures and the effect of residual confounding bias in claims database studies. J Clin Psychopharmacol 2004, 24:632-638.
Wu Q., Bencaz A.F., Hentz J.G., Crowell M.D. Selective serotonin reuptake inhibitor treatment and risk of fractures: a meta-analysis of cohort and case-control studies. Osteoporos Int 2012, 23:365-375.
Liu B., Anderson G., Mittmann N., To T., Axcell T., Shear N. Use of selective serotonin-reuptake inhibitors or tricyclic antidepressants and risk of hip fractures in elderly people. Lancet 1998, 351:1303-1307.
Ensrud K.E., Blackwell T., Mangione C.M., et al. Central nervous system active medications and risk for fractures in older women. Arch Intern Med 2003, 163:949-957.
Verdel B.M., Souverein P.C., Egberts T.C., van Staa T.P., Leufkens H.G., de V.F. Use of antidepressant drugs and risk of osteoporotic and non-osteoporotic fractures. Bone 2010, 47:604-609.
Vestergaard P., Rejnmark L., Mosekilde L. Anxiolytics, sedatives, antidepressants, neuroleptics and the risk of fracture. Osteoporos Int 2006, 17:807-816.
van den Brand M.W., Pouwels S., Samson M.M., et al. Use of anti-depressants and the risk of fracture of the hip or femur. Osteoporos Int 2009, 20:1705-1713.
Vestergaard P., Rejnmark L., Mosekilde L. Selective serotonin reuptake inhibitors and other antidepressants and risk of fracture. Calcif Tissue Int 2008, 82:92-101.
Hubbard R., Farrington P., Smith C., Smeeth L., Tattersfield A. Exposure to tricyclic and selective serotonin reuptake inhibitor antidepressants and the risk of hip fracture. Am J Epidemiol 2003, 158:77-84.
Coupland C., Dhiman P., Morriss R., Arthur A., Barton G., Hippisley-Cox J. Antidepressant use and risk of adverse outcomes in older people: population based cohort study. BMJ 2011, 343:d4551.
Diem S.J., Blackwell T.L., Stone K.L., et al. Use of antidepressant medications and risk of fracture in older women. Calcif Tissue Int 2011, 88:476-484.
Lewis C.E., Ewing S.K., Taylor B.C., et al. Predictors of non-spine fracture in elderly men: the MrOS study. J Bone Miner Res 2007, 22:211-219.
Ziere G., Dieleman J.P., van der Cammen T.J., Hofman A., Pols H.A., Stricker B.H. Selective serotonin reuptake inhibiting antidepressants are associated with an increased risk of nonvertebral fractures. J Clin Psychopharmacol 2008, 28:411-417.
Gagne J.J., Patrick A.R., Mogun H., Solomon D.H. Antidepressants and fracture risk in older adults: a comparative safety analysis. Clin Pharmacol Ther 2011, 89:880-887.
Kerse N., Flicker L., Pfaff J.J., et al. Falls, depression and antidepressants in later life: a large primary care appraisal. PLoS One 2008, 3:e2423.
Hegeman J., van den Bemt B., Weerdesteyn V., Nienhuis B., van L.J., Duysens J. Unraveling the association between SSRI use and falls: an experimental study of risk factors for accidental falls in long-term paroxetine users. Clin Neuropharmacol 2011, 34:210-215.
Hoorn E.J., Liamis G., Zietse R., Zillikens M.C. Hyponatremia and bone: an emerging relationship. Nat Rev Endocrinol 2011, 8:33-39.
Verbalis J.G., Barsony J., Sugimura Y., et al. Hyponatremia-induced osteoporosis. J Bone Miner Res 2010, 25:554-563.
Gangavati A., Hajjar I., Quach L., et al. Hypertension, orthostatic hypotension, and the risk of falls in a community-dwelling elderly population: the maintenance of balance, independent living, intellect, and zest in the elderly of Boston study. J Am Geriatr Soc 2011, 59:383-389.
Swenson J.R., Doucette S., Fergusson D. Adverse cardiovascular events in antidepressant trials involving high-risk patients: a systematic review of randomized trials. Can J Psychiatry 2006, 51:923-929.
Haney E.M., Warden S.J., Bliziotes M.M. Effects of selective serotonin reuptake inhibitors on bone health in adults: time for recommendations about screening, prevention and management?. Bone 2010, 46:13-17.
Kanis J.A., Johnell O., Oden A., Johansson H., Mac Closkey E. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 2008, 19:385-397.
